Philippines Welcomes the Arrival of COVID-19 Vaccines via COVAX Facility

Joint press release by DOH, UNICEF, WHO, GAVI, CEPI

04 March 2021
First batch of COVID-19 vaccine doses committed by the COVAX Facility to the Philippines has arrived in Manila
COVAX Facility
First batch of COVID-19 vaccine doses committed by the COVAX Facility to the Philippines has arrived in Manila on 4 March 2021

04 March 2021, Manila - Today, more than 480,000 doses of AstraZeneca vaccines arrived in the Philippines from the COVAX Facility, the international partnership established to ensure equitable distribution of COVID-19 vaccines around the world. The Philippines is among the first countries in Southeast Asia to receive vaccines from the COVAX Facility. COVAX is co-led by Gavi, the Vaccine Alliance, the World Health Organization (WHO) and the Coalition for Epidemic Preparedness Innovations (CEPI), working in partnership with UNICEF as well as the World Bank, civil society organisations, manufacturers, and others.

"The long days and nights of waiting are finally over. These vaccines will be of great help to our valiant healthcare workers who have been at the forefront of the battle against the COVID-19 pandemic. With every dose that we will administer, we are inching towards a safer recovery from this pandemic. So, let us put our trust in science, in vaccines. Together, we will rise as a nation and heal as one,” says Department of Health Secretary Francisco T. Duque III.

Officials from the Philippines’ Inter-Agency Task Force on the Management of Emerging Infectious Diseases (IATF), Department of Health (DOH), World Health Organization (WHO) and UNICEF Philippines received the vaccine doses at the Ninoy Aquino International Airport. The Philippine Government will lead the rollout of the COVID-19 vaccination campaign.

The COVAX Facility leads an unprecedented effort to provide at least 2 billion doses of COVID-19 vaccines by the end of 2021 to low- and middle-income countries. For several months, COVAX partners have been supporting governments and partners in readiness efforts, in preparation for this moment. This includes assisting with the development of national vaccination plans, support for cold chain infrastructure, as well as stockpiling of half a billion syringes and safety boxes for their disposal, masks, gloves and other equipment to ensure that there is enough equipment for healt h workers to start vaccinating priority groups as soon as possible.

The WHO launched the Access to COVID-19 Tools (ACT) Accelerator, a global collaboration to accelerate development, production, and equitable access to COVID-19 diagnostics, therapeutics, and vaccines. COVAX is the vaccines pillar of the ACT Accelerator and is led jointly by Gavi, WHO, the CEPI, and UNICEF, which is leading vaccine procurement and delivery operations. WHO is tasked with ensuring fair allocation and prioritization of countries eligible to receive vaccines from the COVAX Facility.

“WHO joins partners and the people of the Philippines in welcoming the arrival of COVID-19 vaccines through the COVAX Facility. These vaccines coming through COVAX will help protect up to 20% of the population in the country during this year, including healthcare workers, other frontline workers and the elderly – groups who are most at risk. The COVID-19 vaccines are proven to protect people from severe disease and death. Used together with public health measures currently in place – wearing masks, physical distancing, avoiding large groups, and washing hands frequently – will help mitigate the effects of the pandemic by reducing deaths and severe disease. We all welcome the addition of vaccines to the available tools in the country which, when used to scale, will contribute to gradual return of day-to-day activities and economic revival in the country. The delivery of COVID-19 vaccines in the Philippines is a powerful step in that direction,” said Dr. Rabindra Abeyasinghe, WHO Representative to the Philippines.

UNICEF is leading the procurement and delivery of COVID-19 vaccines through COVAX facility to countries - the biggest, most sophisticated ground operation in the history of immunization. In the Philippines, apart from supporting COVID-19 vaccine introduction and roll out, UNICEF continues to support the immunization programmes of the government through planning, cold chain and vaccine management, technical know-how and training. Building on over 70 years of experience in providing simple, effective and accurate information to build public knowledge, awareness and confidence in vaccines, UNICEF is working with partners to ensure that local communities are engaged in the overall vaccination process.

“Vaccines are safe and effective. The COVID-19 pandemic has become a child rights crisis which we need to end as fast as possible. The longer the pandemic goes on, the more intense the impact on people, especially on children’s health, rights to education, nutrition, protection and mental health. COVID-19 vaccination should be part of a larger strategy to strengthen health systems for children and families in the Philippines for the long-term,” says UNICEF Philippines Representative Oyunsaikhan Dendevnorov.

The COVAX Facility aims to procure 2 billion doses by the end of 2021. The vaccines are intended to protect frontline health care and social workers, as well as high risk and vulnerable people. COVAX was set up to address concerns around fairness and making vaccines available to all. To control and end the global pandemic, vaccines must be available to all. ###

Media contacts

Niko Wieland
Chief of Communication
UNICEF Philippines
Tel: +63 917 867 8366
Marge Francia
Advocacy & Communication Specialist
UNICEF Philippines
Tel: +63 917 858 9447

About COVAX Facility

COVAX is co-led by CEPI, Gavi and WHO – working in partnership with UNICEF as key implementation partner, developed and developing country vaccine manufacturers, the World Bank, and others. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower-income countries.

CEPI is leading on the COVAX vaccine research and development portfolio , and investing in R&D across a variety of promising candidates, with the goal to support development of three safe and effective vaccines which can be made available to countries participating in the COVAX Facility. As part of this work, CEPI has secured first right of refusal to potentially over one billion doses for the COVAX Facility to a number of candidates, and made strategic investments in vaccine manufacturing, which includes reserving capacity to manufacture doses of COVAX vaccines at a network of facilities, and securing glass vials to hold 2 billion doses of vaccine.

Gavi is leading on procurement and delivery for COVAX, coordinating the design and implementation of the COVAX Facility and the COVAX AMC and working with Alliance partners UNICEF and WHO, along with governments, to ensure country readiness and delivery. The COVAX Facility is the global pooled procurement mechanism for COVID-19 vaccines through which COVAX will ensure fair and equitable access to vaccines for all 190 participating economies, using an allocation framework formulated by WHO. The COVAX Facility will do this by pooling buying power from participating economies and providing volume guarantees across a range of promising vaccine candidates. The Gavi COVAX AMC is the financing mechanism that will support the participation of 92 low- and middle-income countries in the Facility, enabling access to donor-funded doses of safe and effective vaccines. UNICEF and the Pan-American Health Organization (PAHO) will be acting as procurement coordinators for the COVAX Facility, helping deliver vaccines to all participants.

WHO has multiple roles within the COVAX: among other things it supports countries as they prepare to receive and administer vaccines and does so in partnership with UNICEF. It provides normative guidance on vaccine policy, regulation, safety, R&D, allocation, and country readiness and delivery. Its Strategic Advisory Group of Experts (SAGE) on Immunization develops evidence-based immunization policy recommendations. Its Emergency Use Listing (EUL)/prequalification programmes ensure harmonized review and authorization across member states. It provides global coordination and member state support on vaccine safety monitoring. It developed the target product profiles for COVID-19 vaccines and provides R&D technical coordination. Along with COVAX partners, it is developing a no-fault compensation scheme for indemnification and liability issues. COVAX is part of the Act accelerator which WHO launched with partners in 2020.

UNICEF is leveraging its experience as the largest single vaccine buyer in the world and working with manufacturers and partners on the procurement of COVID-19 vaccine doses, as well as freight, logistics and storage. UNICEF already procures more than 2 billion doses of vaccines annually for routine immunization and outbreak response on behalf of nearly 100 countries. In collaboration with the PAHO Revolving Fund, UNICEF is leading efforts to procure and supply doses of COVID-19 vaccines for COVAX. In addition, UNICEF and WHO are working with governments around the clock to ensure that countries are ready to receive the vaccines, with appropriate cold chain equipment in place and health workers trained to dispense them. UNICEF is also playing a lead role in efforts to foster trust in vaccines, delivering vaccine confidence communications and tracking and addressing misinformation around the world.


UNICEF promotes the rights and wellbeing of every child, in everything we do. Together with our partners, we work in 190 countries and territories to translate that commitment into practical action, focusing special effort on reaching the most vulnerable and excluded children, to the benefit of all children, everywhere.

For more information about UNICEF and its work for children in the Philippines, visit

Follow UNICEF Philippines on FacebookTwitter and Instagram.